SCHEMBL23218524

SCHEMBL23218524

CCOC(=O)Cc1cccc(F)c1OCc1coc2ccc(-c3cccc(CN)c3F)cc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH2 P05091 3/20 0.34
ALOX5 P09917 1/20 0.34
PTGS2 P35354 2/20 0.34
MEN1 O00255 5/20 0.33
KMT2A Q03164 5/20 0.33
POLB P06746 4/20 0.33
MAPT P10636 2/20 0.33
GAA P10253 2/20 0.33
TGFBR1 P36897 1/20 0.33
PTGS1 P23219 1/20 0.33
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
THRB P10828 1/20 0.32
DPP4 P27487 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852951 1.00 ALDH2 (0.34) ALDH2ALOX5PTGS2MEN1KMT2A
SCHEMBL23218556 0.89 CFD (0.42) ALDH2PTGS2MEN1KMT2APOLB
SCHEMBL29852904 0.89 CFD (0.42) ALDH2PTGS2MEN1KMT2APOLB
SCHEMBL29592722 0.89 PPARD (0.38) CFD
SCHEMBL23218238 0.89 PPARD (0.38) CFD
SCHEMBL23219095 0.88 CFD (0.41) MEN1KMT2APOLBMAPTGAA
SCHEMBL29853070 0.88 CFD (0.41) MEN1KMT2APOLBMAPTGAA
SCHEMBL23218335 0.87 CFD (0.37) ALDH2PTGS2MEN1KMT2APOLB
SCHEMBL29852715 0.87 CFD (0.37) ALDH2PTGS2MEN1KMT2APOLB
SCHEMBL23218397 0.85 CFD (0.38) ALDH2PTGS2MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB ALDH2 3755/4885ALOX5 317/4885PTGS2 1208/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB ALDH2 4100/4885ALOX5 260/4885PTGS2 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.